Correlation Between Virpax Pharmaceuticals and Eliem Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Virpax Pharmaceuticals and Eliem Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Virpax Pharmaceuticals and Eliem Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Virpax Pharmaceuticals and Eliem Therapeutics, you can compare the effects of market volatilities on Virpax Pharmaceuticals and Eliem Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Virpax Pharmaceuticals with a short position of Eliem Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Virpax Pharmaceuticals and Eliem Therapeutics.

Diversification Opportunities for Virpax Pharmaceuticals and Eliem Therapeutics

0.53
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Virpax and Eliem is 0.53. Overlapping area represents the amount of risk that can be diversified away by holding Virpax Pharmaceuticals and Eliem Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Eliem Therapeutics and Virpax Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Virpax Pharmaceuticals are associated (or correlated) with Eliem Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Eliem Therapeutics has no effect on the direction of Virpax Pharmaceuticals i.e., Virpax Pharmaceuticals and Eliem Therapeutics go up and down completely randomly.

Pair Corralation between Virpax Pharmaceuticals and Eliem Therapeutics

Given the investment horizon of 90 days Virpax Pharmaceuticals is expected to under-perform the Eliem Therapeutics. In addition to that, Virpax Pharmaceuticals is 1.36 times more volatile than Eliem Therapeutics. It trades about -0.29 of its total potential returns per unit of risk. Eliem Therapeutics is currently generating about -0.21 per unit of volatility. If you would invest  383.00  in Eliem Therapeutics on September 1, 2024 and sell it today you would lose (79.00) from holding Eliem Therapeutics or give up 20.63% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy95.24%
ValuesDaily Returns

Virpax Pharmaceuticals  vs.  Eliem Therapeutics

 Performance 
       Timeline  
Virpax Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Virpax Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.
Eliem Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Eliem Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.

Virpax Pharmaceuticals and Eliem Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Virpax Pharmaceuticals and Eliem Therapeutics

The main advantage of trading using opposite Virpax Pharmaceuticals and Eliem Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Virpax Pharmaceuticals position performs unexpectedly, Eliem Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eliem Therapeutics will offset losses from the drop in Eliem Therapeutics' long position.
The idea behind Virpax Pharmaceuticals and Eliem Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Other Complementary Tools

Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Transaction History
View history of all your transactions and understand their impact on performance
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges